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Introduction
Neurodegenerative diseases affect millions of Americans each year, and there are
currently very few treatments available. Neurodegenerative diseases cause selective loss of
neurons and can affect multiple systems of the body (Kovacs 2014). Examples of
neurodegenerative diseases include Alzheimer’s disease, Parkinson’s disease, Huntington’s
disease, and amyotrophic lateral sclerosis, more commonly known as ALS or Lou Gehrig’s
disease. Age is the most common risk factor for developing neurodegeneration. As the elderly
population has increased in recent years, the prevalence of neurodegenerative disease has also
increased greatly over the last decade (Alzheimer’s Association 2017). An estimated 40 million
people worldwide suffer from some form of dementia due to neurodegenerative disease
(Prince et al. 2013). Additionally, this figure is projected to double every 20 years until at least
2050, making this a global health crisis (Scheltens et al. 2016).
Neurodegenerative diseases are notoriously difficult to treat because they are
commonly caused by a combination of both genetic and environmental factors. The inability to
pinpoint one specific cause for many of these diseases makes it difficult to develop treatments;
researchers are unsure which parts of the brain should be targeted by treatments. Due to the
complicated nature of these diseases, there are currently no cures and only a few symptomatic
treatments of varying effectiveness available for any of the more common neurodegenerative
diseases (Heemels 2016).
Given the complex nature of these diseases, researchers have been considering new
approaches to treatment. One such approach is gene therapy, “the use of nucleic acids (DNA or
RNA) for the treatment, cure, or prevention of human disorders” (Kaufmann et al. 2013). Gene
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therapy can be used to treat genetic diseases by replacing a mutated gene with a functional
copy. However, gene therapy can also be used to treat diseases that do not have a genetic
cause. For example, the first gene therapy in the United States was recently approved by the
FDA to treat a rare form of pediatric leukemia. The treatment, known as CAR-T cell therapy,
genetically alters the patient’s own immune cells to express a new protein in order to better
equip them to destroy cancer cells (Collins 2017). These modified cells are then re-infused into
the patient’s body to fight the disease.
Although gene therapy can be used to add a new gene to compensate for a
non-functional one, there are also many cases where precisely modifying an existing gene
would be useful in treating a disease. This approach is known as gene editing, the manipulation
of the human genome to achieve a therapeutic effect (Maeder and Gersbach 2016). The
current approach to gene editing is the use of programmable nucleases. These are nucleases
that recognize a specific target DNA sequence and generate a double stranded break in the
DNA at that location. There are three major types of programmable nucleases: zinc finger
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas9 (Gaj
et al. 2016). The basic approach utilizes a cellular mechanism known as non-homologous end
joining (NHEJ). The creation of a double stranded break in the DNA triggers the cell’s repair
machinery to rejoin the broken ends of the DNA. This occurs in a highly-error prone manner
that often leads to the insertion or deletion of one or more base pairs (Carroll 2011). These
changes in the DNA sequence can alter the function of a gene dramatically, potentially creating
what is known as a knockout mutation, a non-functional mutation in the protein-coding region
of a gene. These mutations cause a loss of function in that gene, allowing researchers to study
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the phenotypic effects of that gene being lost. A variation of this approach involves introducing
a new sequence at the location of the double stranded break. If a homologous sequence is
present, homology-directed repair (HDR) can occur, leading to the insertion of a new sequence.
Researchers have considered the possibilities of using gene editing to replace mutant
sequences with wild-type sequences for diseases where eliminating a defective allele would not
be sufficient to restore a normal phenotype, such as hemophilia (Nathwani et al. 2017). All
three types of programmable nucleases can be used both to create knockout mutations and to
insert new DNA sequences.
The first programmable nucleases developed to edit gene sequences were zinc finger
nucleases (ZFNs). ZFNs have two separate domains: a DNA binding domain and a nuclease
domain from the FokI restriction enzyme (Carroll 2011). The zinc finger portion of a ZFN
consists of an amino acid sequence bound to a zinc atom; this sequence determines the ZFN’s
specificity for target DNA sequences (Carroll 2011). The FokI domain then cleaves the target
DNA, generating a double-stranded break. However, because it is difficult to manipulate and
engineer ZFNs, the technique has lost popularity.
A newer technique for gene editing is transcription activator-like effector nucleases,
TALENs, which were first used in 2009 (Gaj et al. 2016). TALENs work using a mechanism similar
to ZFNs: they bind to a specific sequence in the DNA and generate a double-stranded break at
that location, which usually leads to error-prone repair of the sequence, thereby disrupting
gene function (Gaj et al. 2016). One of the major reasons that TALENs displaced ZFNs in the
field of gene editing is their ease of manipulation. TALENs use a simple, modular DNA
recognition code, making them easier to design to recognize a specific sequence (Gaj et al.
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2016). However, TALENs are much larger proteins than ZFNs. This makes it very challenging to
deliver them into target cells using traditional vectors, such as adeno-associated virus (AAV)
and lentivirus vectors (Gaj et al. 2016). For these reasons, there has been a need for a
technique that is easier to use, yet is still able to specifically target DNA sequences for editing.
In 2012, a technology now known as CRISPR-Cas9 was discovered, which also allows
researchers to make double-stranded breaks in DNA by targeting a specific location with a
guide RNA (gRNA) that is bound by a Cas9 nuclease (Jinek et al. 2012). CRISPRs, clustered
regularly interspaced short palindromic repeats, are repetitive DNA sequences that are found
naturally in bacteria and give bacterial cells immunity against invading viruses by using the Cas9
nuclease to cleave the genetic material of the virus (Jinek et al. 2012). Like TALENs and ZFNs,
CRISPR-Cas9 can also be used to generate knockout mutations and insert new DNA sequences.
To insert a new DNA sequence, all that researchers have to do is insert a copy of the desired
DNA sequence along with the Cas9 nuclease and gRNA. Once Cas9 generates a break in the
DNA, the cell’s homology-directed repair (HDR) system can insert the desired DNA into the
space left by the double-stranded break (Dance 2015). The inserted DNA sequence can be
anywhere from a few to thousands of base pairs in size, providing an extremely wide range of
possibilities for gene editing.
While conceptually similar to the previously discovered ZFNs and TALENs, CRISPR-Cas9
allows researchers to much more simply and efficiently target specific locations in a gene (Jinek
et al. 2012). CRISPR-Cas9 works on the principle of complementary base pair interactions
between nucleic acids, while ZFNs and TALENs are based on protein/nucleic acid interactions.
The ease of developing a nucleotide sequence that can recognize another nucleotide sequence
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makes CRISPR-Cas9 much simpler to use than other techniques. However, all three techniques
present the risk of off-target effects (Gaj et al. 2016). If the programmable nuclease binds to the
incorrect DNA sequence, it could result in a mutation in a non-target gene. Due to its relative
simplicity and current popularity, I will focus on using CRISPR-Cas9 as a form of gene therapy.
While the main application of CRISPR-Cas9 with respect to neurodegenerative disease
has been the creation of animal models, great potential exists for its use in human gene
therapy. In this thesis, I will review how gene therapy could potentially be used to treat
neurodegenerative disease. Specifically, I will evaluate the use of gene therapy in treatment of
Huntington’s disease, a classic Mendelian disease, and Alzheimer’s disease, a
neurodegenerative disease that involves both genetic and environmental factors. I will also
discuss the potential for using the recently discovered gene editing technology, CRISPR-Cas9, to
treat these diseases.
Huntington’s Disease
One well-studied neurodegenerative disease is Huntington’s disease (HD), which affects
about 30,000 people in the U.S. each year (Huntington’s Disease Society of America 2017). HD
causes progressive deterioration of nerve cells in the brain, leading to loss of motor control,
balance, and in most cases, decreased cognitive function (Roos 2010). The disease has a
delayed onset, with symptoms typically not appearing until patients are 30 to 50 years old
(Roos 2010). Death occurs in most patients 15-20 years after the onset of symptoms with these
years marked by increasingly debilitating symptoms (Ross and Tabrizi 2011). Some of the main
symptoms of the disease that affect mobility include bradykinesia (slowed movements), chorea
(involuntary muscle movements), and rigidity (Phillips et al. 2008). Cognitively, Huntington’s
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disease affects judgment and planning skills and working memory function, and the disease
causes various psychiatric disturbances including irritability and aggression (Phillips et al. 2008).
Many patients also experience depression and suicidal thoughts as the disease progresses
(Wyant et al. 2017).
Huntington’s disease displays an autosomal dominant pattern of inheritance, meaning
that if only one mutant copy of the huntingtin (HTT) gene is inherited, that individual is at very
high risk of developing Huntington’s disease later in life. The wild-type form of the huntingtin
protein contains several evolutionarily conserved regions found in both vertebrates and
invertebrates, suggesting that the protein has a critical function. The huntingtin protein is
expressed widely throughout the mammalian brain, with the highest concentration of
huntingtin-rich neurons found in the cerebral cortex and the hippocampus. In addition,
huntingtin is essential for normal brain development (Reiner et al. 2011). A study investigating
the effects of a knockout of the HTT gene only in the brains of mice mice showed that
decreased HTT expression led to decreased brain size at three months of age, and significant
neurodegeneration was observed by four to six months (Liu and Zeitlin 2017). Although the
exact function of the huntingtin protein is still unknown, there are a wide variety of proposed
functions including neurogenesis, synaptogenesis, and cell signaling (Liu and Zeitlin 2017).
A pathogenic mutation within the HTT gene of people with HD causes production of a
defective huntingtin protein, which accumulates within the brain, leading to impaired function
of neurons and eventually death. This toxic gain-of-function mutation leads to an expansion of
a polyglutamine (polyQ) tract encoded in the HTT gene (Yang et al. 2017). In the wild-type
huntingtin gene, the CAG sequence that encodes glutamine is repeated 9-35 times, but in
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disease-causing alleles, it is repeated more than 35 times (Saudou and Humbert 2016). While
the exact mechanism of pathogenesis is unknown, there are numerous ways that the mutant
huntingtin protein might produce its toxic effects, including mitochondrial dysfunction,
disruption of transcription, and dominant negative interactions between the wild-type and
mutant forms of huntingtin (Jimenez-Sanchez et al. 2017).
There have been many clinical trials of proposed treatments for Huntington’s disease,
including drug and gene therapies, but treatments are primarily aimed at symptom
management (Wyant et al. 2017). The current drug therapies focus on treating the motor and
psychiatric symptoms of the disease. One drug that is commonly used for symptomatic
treatment of chorea is tetrabenazine, which is one of the only FDA-approved drugs designed to
suppress the involuntary movements associated with the disease (Frank 2014). However, this
drug has no impact on disease progression and there are many potential negative side effects
(Frank 2014). Other drugs focus on preservation of neurons, with treatments focusing on the
neurotransmitters dopamine, glutamate, and gamma-aminobutyric acid (Frank 2014). However,
the effectiveness of these treatments to date has been limited, with no impact on disease
progression or onset, leading to an increased need for more effective treatments (Frank 2014).
One potential treatment route that has been considered for Huntington’s disease is
gene editing. Recently, a promising study was performed in a mouse model of HD. Researchers
first created a knock-in model of HD in mice, replacing the wild-type HTT gene with the mutant
form (Menalled et al. 2003). This led to expression of the mutant huntingtin protein (mHTT) in
the mice, with significant mutant huntingtin accumulation found in the neurons of 9-10 month
old mice (Yang et al. 2017). The researchers then injected the brains of these 9-10 month old
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mice with two AAV vectors: one expressing the gRNA (AAV-HTT-gRNA) and one expressing the
Cas9 protein (AAV-CMV-Cas9) (Yang et al. 2017). They found that three months after
treatment, expression of mHTT in striatal neuronal cells was significantly decreased in mice
treated with the gRNA and Cas9 vectors, but not in those mice treated with a control gRNA
(Yang et al. 2017). Additionally, the researchers saw that there was a substantial decrease in
the aggregates of defective huntingtin protein in the brain, which led to improved motor
function (Yang et al. 2017). While this treatment has not yet been tested in human patients
with HD, if similar results were seen in humans then CRISPR-Cas9 could become a breakthrough
treatment for HD.
Another form of gene therapy that has potential for use in treatment of HD is gene
silencing. This group of techniques, which includes RNA interference (RNAi), microRNAs
(miRNAs), and antisense oligonucleotides (ASOs), can degrade target mRNA or prevent
translation of a target mRNA into protein (Wyant et al. 2017). RNAi works via short interfering
RNAs (siRNAs) that bind to target mRNA and activate the RNA-induced silencing complex,
leading to degradation of the mRNA. This greatly decreases the amount of target mRNA that is
available to be translated into protein (Wyant et al. 2017). miRNAs work by a related
mechanism; they are short RNAs that can block translation or degrade target mRNA (Keiser et
al. 2016). A study performed in a mouse model of HD used an AAV vector containing miRNAs
targeting mutant HTT mRNA to examine the effects on mutant huntingtin expression. They
found that there was an approximately 50% decrease in both mutant HTT mRNA and huntingtin
protein production in the striatum of treated mice (Stanek et al. 2014). The treated mice also
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demonstrated improved motor function after RNAi was performed, making this a potential
treatment for HD (Stanek et al. 2014).
An alternative approach uses ASOs, (short, single-stranded nucleic acids that can bind to
complementary mRNAs) which trigger degradation of transcripts as well as prevent translation
of the mRNA into protein (Wyant et al. 2017). ASOs can bind pre-mRNAs in the nucleus,
triggering recruitment of an enzyme that degrades the mRNA before it is mature and
transported to the cytoplasm for translation (Skotte et al. 2014). These molecules can also bind
to mRNAs in the cytoplasm, interfering with translation (Skotte et al. 2014). To target HD, ASOs
that are capable of specifically targeting only the mutant HTT mRNA must be designed. In the
case of Huntington’s disease, these ASOs would lead to reduced production of the mutant
protein, potentially slowing disease progression or even preventing disease onset altogether
(Wyant et al. 2017). While this technique has only been tested in cultured cells, it shows
potential as a form of treatment for HD.
One major challenge facing researchers is the delivery of gene silencing molecules into
cells (Wild and Tabrizi 2017). In the case of RNAi or miRNAs, a vector is required for delivery.
However, in many cases, vector size limits the length of the DNA sequence that can be
introduced (Wild and Tabrizi 2017). For this reason, researchers have begun to search for other
methods of gene silencing that do not require a vector, such as ASOs (Liu et al. 2017). Unlike
RNAi or miRNAs, ASOs can be delivered directly to cells without a vector (Kaczmarek et al.
2017). In previous studies, researchers have been able to successfully deliver ASOs to the brain
by directly injecting them into the cerebrospinal fluid (DeVos and Miller 2013). When using this
method of delivery, the researchers found that the ASOs were evenly distributed throughout
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tissues, rather than being concentrated in one area of the brain. This indicated that the ASOs
were being taken up by cells via active transport, although the exact mechanism through which
uptake occurs remains largely unknown (DeVos and Miller 2013).
Once gene silencing molecules have been successfully delivered into cells, researchers
have to be concerned with the degradation of these molecules. siRNAs and miRNAs are broken
down much more quickly than ASOs, meaning that frequent treatments might be required in
order to achieve the desired effects (Wyant et al. 2017). ASOs, on the other hand, are degraded
at a slower rate compared with other small RNA molecules (Evers et al. 2015). This slower
degradation rate is due to a chemically modified backbone found in ASOs. There are no
enzymes present in the cell that can recognize and cleave these backbones, and so the ASOs
may remain active for an extended period of time (Evers et al. 2015). Due to this longer lifespan
within the cell, treatments may not be required as frequently, making ASOs a promising
treatment for HD.
In addition to the challenges of delivery and degradation, off-target effects are an issue
with ASOs, RNAi, and miRNAs. In many cases, the specificity of these nucleotide sequences is
not high enough to guarantee that only the mutant mRNA will be targeted for degradation, yet
function of the wild-type allele must be preserved while simultaneously eliminating function of
the mutant allele (Wyant et al. 2017). Additionally, wild-type mRNAs from unrelated genes with
sequences similar to the sequence of the mutant HTT allele may be targeted by the ASOs,
producing an off-target effect and blocking translation of non-HTT mRNAs (Wyant et al. 2017).
While off-target effects have been observed with ASOs, there is some evidence that they have
higher sequence specificity and produce fewer off-target effects than other gene silencing
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mechanisms (Wild and Tabrizi 2017). Due to this specificity, there is less risk of the ASO
targeting wild-type HTT mRNAs in addition to mutant mRNAs, significantly increasing its appeal
as a treatment for HD (Wyant et al. 2017).
Parkinson’s Disease
Parkinson’s disease (PD) is another neurodegenerative disease that has the potential to
be treated with gene therapy. PD is the second most common neurodegenerative disorder after
Alzheimer’s disease, affecting 2-3% of the population over the age of 65 (Kalia and Lang 2015;
Williams-Gray and Worth 2016). Given the growing size of the elderly population in the United
States, Parkinson’s disease is a risk for many. Similar to Huntington’s disease, Parkinson’s
disease has both physical and psychiatric effects. Some of the physical symptoms seen in those
with the disease include bradykinesia, tremors while at rest, or rigidity of the limbs
(Williams-Gray and Worth 2016). Mood and sleep disorders, hallucinations, and depression are
just a few of the psychiatric symptoms seen in many patients as the disease progresses (Kalia
and Lang 2015).
While researchers know that development of Parkinson’s disease involves both genetic
and environmental factors, the pathology of PD is not entirely understood. As a result,
researchers have been unable to develop a highly effective treatment, let alone a cure, for the
disease. Treatment options currently available include drugs that focus on treating the
symptoms of the disease, such as motor dysfunction and mood disorders (Williams-Gray and
Worth 2016). Similar to Huntington’s disease, these treatments are often ineffective or, at
best, mildly effective for a short period of time; they have no effect on disease progression.
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One of the most common drug therapies used to treat Parkinson’s disease involves
increasing the production of dopamine in the brain (Coune et al. 2012). As PD progresses,
neurons in the brain that are responsible for producing dopamine, known as dopaminergic
neurons, degenerate and eventually die. The death of these neurons leads to a dopamine
deficiency, causing some of the motor symptoms associated with the disease (Kalia and Lang
2015). One type of drug therapy, L-dopa therapy, has been used to treat symptoms of
Parkinson’s disease since 1969; it works by increasing production of dopamine in the brain’s
remaining dopaminergic neurons (Coune et al. 2012). However, there are many disadvantages
to this treatment. L-dopa therapy requires frequent administrations in high doses in order to
achieve any improvement in symptom severity; such high doses can cause adverse side effects
(Coune et al. 2012). Additionally, over long periods of time, treatment can become ineffective
at controlling motor symptoms in many patients (Lin et al. 2017).
Like HD, the relatively low effectiveness of available drug therapies for PD has led
researchers to consider gene therapy as an option. However, in contrast to HD, where a single
mutation in a specific gene results in the HD phenotype, development of PD involves numerous
genetic and environmental factors. While some specific genetic variants have been shown to be
associated with the disease, environmental factors still play a significant role. This suggests that
targeting a specific genetic variant would not be an effective approach to disease treatment, as
it is with HD. An additional challenge when treating PD is that most cases of the disease are
sporadic, with only 2-3% of cases being familial (Williams-Gray and Worth 2016). Because the
majority of cases are sporadic, I will be focusing on the use of gene therapy to treat this form of
the disease.
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When considering gene therapy for PD, researchers must consider the overall goal of
treatment. In HD, gene therapy aims to eliminate expression of the toxic huntingtin protein by
preventing expression of a specific gene. However, in PD, the goal of gene therapy would be to
promote the expression of proteins that protect neurons and stimulate neuronal growth. For
this reason, techniques such as ASOs or miRNA that prevent gene expression would not be the
right approach for treatment. Instead, researchers have considered using gene therapy to
express neurotrophic factors in the brain to protect neurons. Gene therapy using two
neurotrophic factors, glial-cell derived neurotrophic factors (GDNF) and neurturin (NTN) are of
particular interest to researchers. These factors are known to play a role in maintenance of the
nervous system and potentially in survival of dopaminergic neurons (Lin et al. 2017). Utilizing
these factors in treatment could be a way to prevent the death of dopaminergic neurons seen
in both familial and sporadic forms of Parkinson’s disease.
By the end of 2017, three clinical trials testing the safety and efficacy of gene therapy as
a form of treatment for Parkinson’s disease had been completed. One of these trials involved
the surgical insertion of an AAV2 vector containing the gene for NTN into the putamen of
patients diagnosed with PD (Olanow et al. 2015). AAV2 is a viral vector that is one of the best
characterized vectors used for gene delivery (Olanow et al. 2015). The treatment, known as
CERE-120, was performed in 24 patients who were then examined every three months for a
total of 15 months. The treatment was well-tolerated by patients, and in the second part of the
study, the researchers evaluated patients’ motor function (Olanow et al. 2015). Over the course
of the 15-month study, no significant improvements in motor function were seen in the
patients who received CERE-120 compared to control subjects (Olanow et al. 2015). However,
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all patients that participated in the trial were in the late stages of PD, so it is possible that
treatment may need to be administered earlier in disease development to be effective (Olanow
et al. 2015). Researchers also hypothesized that the ineffectiveness of the treatment could also
be attributed to impaired transport of the NTN gene from the surgical site to other areas of the
brain (Olanow et al. 2015). However, follow-up studies testing effectiveness of the treatment
when administered to other sites also failed to show any differences in efficacy (Olanow et al.
2015).
While this study was not successful at treating symptoms of PD, it did demonstrate the
safety of using viral vectors as a delivery method for gene therapy. No significant side effects
were found to be associated with the delivery of the AAV2-NTN vector, and weight loss was not
seen as a side effect in any of the treated patients (Olanow et al. 2015). This is particularly
important with a disease like Parkinson’s disease, where significant weight loss can impact
disease progression and increase severity of disease symptoms such as dyskinesia (Ma et al.
2018).
Gene therapy to promote expression of GDNF has also been pursued as a possible
treatment for PD. One study involved injection of an AAV vector directly into the brain of a rat
model of PD. This vector was linked to a promoter that could induce increased expression of
GDNF (Tereshchenko et al. 2014). The researchers found that increased GDNF expression levels
improved motor control and had a protective effect on dopaminergic neurons in treated rats
(Tereshchenko et al. 2014). However, within three weeks of treatment, levels of GDNF had
decreased back to baseline levels. This indicates that frequent treatments would be required in
order to maintain increased levels of GDNF in the brain. Additionally, while significant weight
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loss was not observed in treated rats in this study, other studies have observed severe weight
loss as a side effect of GDNF gene therapy (Manfreddson et al. 2009). This indicates that
increasing levels of GDNF may be a less advantageous form of gene therapy compared to
NTN-based gene therapy.
One of the major benefits of using gene therapy to deliver neurotrophic factors is that
fewer treatments may be required, especially in the case of NTN. Additionally, delivery of viral
vectors to a specific site has become better understood in recent years, making direct delivery
of genes expressing neurotrophic factors a possibility for treatment (Coune et al. 2012). While
L-dopa therapy still remains the standard treatment for PD, it only treats the symptoms of the
disease and requires frequent treatments.
Conclusion
Neurodegenerative diseases affect millions of Americans every year with limited
treatment options available. Those treatments that are available are often minimally effective
and have no impact on disease progression. My thesis has focused on the use of gene therapy
as a possible treatment for some of these devastating diseases, including Huntington’s disease
and Parkinson’s disease. However, there are several different challenges that must be
overcome before gene therapy can be used to treat neurodegenerative disease.
One of the major issues that must be resolved is delivery. Gene editing molecules must
be delivered directly to cells, either through injection or the use of a vector. Vectors limit the
size of the DNA sequence that can be delivered to the cell, indicating that using a molecule that
does not require a vector, such as ASOs, may be more practical for treatment of
neurodegenerative disease. Another challenge facing researchers is specificity. When using a
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technique that targets a specific DNA sequence for editing, there is always the possibility that
the gene editing molecule will target similar sequences and edit those as well. This is a major
problem when considering the use of gene therapy for Huntington’s disease treatment; any
gene silencing molecule that targets the mutant HTT gene or mRNA could also target wild-type
HTT, leading to its degradation. To effectively treat a disease using gene therapy, researchers
must be able to ensure that off-target effects are not occurring.
A final problem to consider is the degradation of gene editing molecules. Even after
successful delivery to the target cells, siRNAs or miRNAs are degraded by the cell at a rapid rate.
More frequent treatments may be required in order to achieve the desired effects, placing a
greater burden on both patients and researchers. In contrast, ASOs have a chemically modified
backbone, that protects them from degradation by RNases (Schoch and Miller 2017). Because
of this increased resistance to degradation, is believed that they may remain active within the
cell for a longer period of time; this may indicate that fewer treatments would be required.
Compared to other methods of gene therapy, ASOs are easier to deliver to cells and
they may remain active within the target cells for an extended period of time. While significant
improvements still need to be made in specificity before any clinical trials can be performed in
humans, ASOs have been shown to be successfully delivered to the brain via injection into the
cerebrospinal fluid of mice. Additionally, the ASOs were evenly distributed throughout the
tissues. The decreased rate of degradation within the cell could also indicate that less frequent
treatments may be required, alleviating some of the stress placed on patients. For these
reasons, I believe that ASOs could be the most feasible method of gene therapy for
Huntington’s disease.
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Given the multitude of genetic and environmental factors involved in development of
PD, treatment using gene therapy will not be as straightforward as with HD. However,
promising clinical trials have been completed. The CERE-120 study demonstrated the safety of
using a vector to deliver neurotrophic factors directly to the brain with very limited adverse
effects. On the basis of side effects, NTN seems to be a better treatment option for PD because
it does not appear to cause severe weight loss, a major side effect that PD researchers want to
avoid. Significant weight loss has been observed in GDNF-based gene therapy; however, results
have varied, and more studies will need to be completed before one neurotrophic factor can be
considered more beneficial for treatment of PD.
Looking forward, there are still many aspects of gene therapy that need to be improved
upon before it can be utilized to treat neurodegenerative diseases. While delivery is one of the
primary issues facing researchers, both specificity and maintenance of gene editing molecules
must be improved. Based on the current literature available, I believe that ASOs are one of the
more promising techniques that could be used in treating HD. While there have been fewer
clinical trials examining the use of gene therapy for PD, treatment that increases levels of NTN
seem to have fewer side effects than GDNF gene therapy. More studies demonstrating safety
and efficacy of gene therapy for neurodegenerative diseases will be required before completing
additional trials in humans, but gene therapy remains one of the most promising potential
treatment routes available to researchers today.
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